Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Relapsed triple-negative breast cancer: challenges and treatment strategies.

Guarneri V, Dieci MV, Conte P.

Drugs. 2013 Aug;73(12):1257-65. doi: 10.1007/s40265-013-0091-6. Review.

PMID:
23842749
2.

Triple-negative breast cancer: advancements in characterization and treatment approach.

Hurvitz S, Mead M.

Curr Opin Obstet Gynecol. 2016 Feb;28(1):59-69. doi: 10.1097/GCO.0000000000000239. Review.

PMID:
26694831
3.

Targeting triple-negative breast cancer: optimising therapeutic outcomes.

Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S.

Ann Oncol. 2012 Sep;23(9):2223-34. doi: 10.1093/annonc/mds067. Epub 2012 Apr 19. Review.

PMID:
22517820
4.

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.

Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA.

Breast Cancer Res. 2014 Aug 8;16(4):406. doi: 10.1186/s13058-014-0406-x.

5.

Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.

Sayed-Ahmed MM, Hafez MM, Al-Shabanah OA, Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Alsheikh A, Al Diab AI, Al-Akeely MH.

Tumori. 2013 Jul-Aug;99(4):545-54. doi: 10.1700/1361.15109.

PMID:
24326846
6.

Recent developments in treatment stratification for metastatic breast cancer.

Barton S, Swanton C.

Drugs. 2011 Nov 12;71(16):2099-113. doi: 10.2165/11594480-000000000-00000. Review.

PMID:
22035512
7.

Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.

Neoplasia. 2014 Jan;16(1):43-72. Erratum in: Neoplasia. 2014 Apr;16(4):375. Neoplasia. 2014 Apr;16(4):375.

8.

Triple Negative Breast Cancer: A Tale of Two Decades.

Ali AM, Ansari JAK, El-Aziz NMA, Abozeed WN, Warith AMA, Alsaleh K, Nabholtz JM.

Anticancer Agents Med Chem. 2017;17(4):491-499. doi: 10.2174/1871520616666160725112335. Review.

PMID:
27456662
9.

mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.

Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin SY.

Clin Cancer Res. 2016 Apr 1;22(7):1699-712. doi: 10.1158/1078-0432.CCR-15-1772. Epub 2015 Nov 6.

10.

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.

Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA.

Clin Cancer Res. 2010 Oct 1;16(19):4702-10. doi: 10.1158/1078-0432.CCR-10-0939. Epub 2010 Sep 21. Review.

11.

[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].

Nowacka-Zawisza M, Krajewska WM.

Postepy Hig Med Dosw (Online). 2013 Nov 26;67:1090-7. Review. Polish.

12.

Triple-negative breast cancer: molecular subtypes and new targets for therapy.

Lehmann BD, Pietenpol JA, Tan AR.

Am Soc Clin Oncol Educ Book. 2015:e31-9. doi: 10.14694/EdBook_AM.2015.35.e31.

13.

Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives.

Carbognin L, Furlanetto J, Vicentini C, Nortilli R, Pilotto S, Brunelli M, Pellini F, Pollini GP, Bria E, Tortora G.

Anticancer Agents Med Chem. 2015;15(1):15-25. Review.

PMID:
25329488
14.

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.

Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS.

Breast Cancer Res. 2014 Apr 7;16(2):R36. doi: 10.1186/bcr3640.

15.

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.

PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.

16.

Therapies for triple negative breast cancer.

Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM.

Expert Opin Pharmacother. 2015 May;16(7):983-98. Review.

PMID:
25881743
17.

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.

Tanino H, Kosaka Y, Nishimiya H, Tanaka Y, Minatani N, Kikuchi M, Shida A, Waraya M, Katoh H, Enomoto T, Sengoku N, Kajita S, Hoffman RM, Watanabe M.

PLoS One. 2016 Dec 9;11(12):e0165721. doi: 10.1371/journal.pone.0165721. eCollection 2016.

18.

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.

Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.

Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y.

19.

Subtyping of triple-negative breast cancer: implications for therapy.

Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA.

Cancer. 2015 Jan 1;121(1):8-16. doi: 10.1002/cncr.28914. Epub 2014 Jul 16. Review.

20.

Triple negative breast cancer: looking for the missing link between biology and treatments.

Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A, D'Aiuto M.

Oncotarget. 2015 Sep 29;6(29):26560-74. doi: 10.18632/oncotarget.5306. Review.

Supplemental Content

Support Center